Research Paper Volume 16, Issue 10 pp 8772—8809
Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses
Figure 7. TME landscapes of the high- and low-risk groups. (A) The differences of stromal score, immune score and ESTIMATE score between the high- and low-risk groups. (B) The differences of infiltrating immune cells between the high- and low-risk groups by single sample gene set enrichment analysis (ssGSEA). (C) The differences of immune function between the high- and low-risk groups by ssGSEA. (D) The differences of immune checkpoint genes expression between the high- and low-risk groups. (E) The differences of HLA-related genes expression between the high- and low-risk groups. (F) The differences of cancer-immunity cycle scores between the high- and low-risk groups. *P < 0.05, **P < 0.01, ***P < 0.001.